Shares of Divi's Laboratories Ltd. (NSE: DIVISLAB) advanced up to 4% on August 3, 2026

Q1 Financial & Operational Highlights The company delivered exceptional top-line and bottom-line growth, heavily fueled by its Custom Synthesis division. Consolidated Growth: Revenue surged 28% year-over-year (YoY). Net profit jumped an impressive 75% YoY. Margin Expansion: EBITDA expanded by 72%, with the EBITDA margin reaching a multi-quarter high of 40.7%. Analyst Note: The Street attributes this sharp margin expansion to favorable operating leverage, inventory benefits, and likely one-off milestone/validation batch payments within custom synthesis contracts. Custom Synthesis (CRDMO): This segment remains the primary growth engine, growing 45%-50% YoY and now accounting for approximately 60% of total revenue. Strategic Focus: Management emphasized a balanced product portfolio and highlighted a strengthening, highly differentiated pipeline in the peptide space, supported by an integrated manufacturing platform. Management Guidance & Outlook While Q1 results were exceptional, management provided measured forward-looking guidance: Revenue: Reiterated confidence in achieving double-digit revenue growth for FY27. Margins: Guided for a full-year gross margin of ~60% (versus the 68% reported in Q1) and indicated that the FY27 EBITDA margin should remain broadly in line with FY26 levels. Analyst Actions & Price Target Revisions Following the earnings beat, three major brokerages now maintain price targets above ₹10,000: Citi (Buy): Raised target price to a Street-high of ₹11,700. Citi highlighted backward integration, operating leverage, and the transition of multiple projects (including peptides and contrast media) from validation to commercial scale. Macquarie (Outperform): Maintained target price at ₹10,200. Macquarie noted that revenue, EBITDA, and net profit beat their estimates by 10%, 33%, and 30%, respectively. JPMorgan (Overweight): Retained target at ₹9,100, remaining constructive on the long-term peptide opportunity.